A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA

Inclusion Criteria: * Clinical diagnosis of small for gestational age, SGA. * Chronological age between 2-6.5 years in girls and 2-7.5 years in boys. Both genders. * Prepubertal stage (Tanner I). * Without catch-up growth in two years after birth. * Height was lower than the mean -2SD of the values of normal children of the same age and gender when participating in the study. * A GH peak concentration \>10µg/L in a provocative test within a year before participate in the study. * Bone age\<Chronological age+1. * Normal glucose regulation：Fasting blood-glucose \< 5.6mmol/L and 2-hour postprandial blood glucose\< 7.8mmol/L. * Gestational age≥Gestational age≥ 36weeks + 4days. * Never accepted growth hormone treatment. * The subjects and their guardians signed informed consent. Exclusion Criteria: * Subjects with Liver and renal insufficiency (ALT \> 2 times of upper limit of normal value, Cr\> upper limit of normal value). * Patients with positive for antibodies to hepatitis B core (anti-HBc), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg)。 * Known highly allergic constitution or allergic to the test drug. * Subjects with diabetes, severe cardiopulmonary and pulmonary disease, and hematological diseases, malignant tumors, or systemic infection, immunocompromised patients and patients with psychosis. * Subjects with other types of abnormal growth and development, such as Turner syndrome, constitutional delay of puberty, Laron syndrome, growth hormone receptor deficiency. * Subjects who have received the treatment of Somatropin or took part in other clinical trial study within 3 months. * Other conditions which in the opinion of the investigator preclude enrollment into the study.